Other languages Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Real-time Estimate Cboe BZX Other stock markets 11:29:47 2024-05-24 am EDT			5-day change	1st Jan Change
32.4 ^USD	-0.90%		-5.58%	+45.60%

May. 16	Transcript : Agios Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:40 AM
May. 02	Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	May. 02
Agios Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises	Feb. 15
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
Servier replonge dans le rouge en raison du dossier Mediator	Feb. 07
Agios Pharmaceuticals Insider Sold Shares Worth $277,397, According to a Recent SEC Filing	Jan. 09
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	Jan. 08
Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints	Jan. 03
Agios' blood disorder drug meets goals of late-stage study	Jan. 03
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	Jan. 03
Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition	Dec. 09
Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes	Nov. 20
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Insider Sell: Agios Pharmaceuticals	23-08-21
Insider Sell: Agios Pharmaceuticals	23-08-10
Agios Pharmaceuticals Signs License Deal With Alnylam for Potential Treatment for Rare Blood Disease	23-08-03
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Insider Sell: Agios Pharmaceuticals	23-06-30
Agios Pharmaceuticals Says Phase 2 Trial of Mitapivat for Sickle Cell Disease Met Primary Endpoint	23-06-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Other languages

Filters